Back to Journals » International Journal of Nanomedicine » Volume 15

A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model

Authors Klapproth AP, Shevtsov M, Stangl S, Li WB, Multhoff G

Received 25 March 2020

Accepted for publication 21 May 2020

Published 30 June 2020 Volume 2020:15 Pages 4677—4689


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas J. Webster

Alexander P Klapproth, 1, 2,* Maxim Shevtsov, 1, 3– 7,* Stefan Stangl, 1 Wei Bo Li, 2 Gabriele Multhoff 1

1Center for Translational Cancer Research Technische Universität München (TranslaTUM), Klinikum Rechts Der Isar, Munich, Germany; 2Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany; 3Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russia; 4Department of Biotechnology, First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia; 5Almazov National Medical Research Centre, Russian Polenov Neurosurgical Institute, St. Petersburg, Russia; 6National Center for Neurosurgery, Nur-Sultan, Kazakhstan; 7Department of Biomedical Cell Technologies, Far Eastern Federal University, Vladivostok, Russia

*These authors contributed equally to this work

Correspondence: Maxim Shevtsov; Wei Bo Li Email [email protected]; [email protected]

Background: Superparamagnetic iron oxide nanoparticles (SPIONs) have displayed multifunctional applications in cancer theranostics following systemic delivery. In an effort to increase the therapeutic potential of local therapies (including focal hyperthermia), nanoparticles can also be administered intratumorally. Therefore, the development of a reliable pharmacokinetic model for the prediction of nanoparticle distribution for both clinically relevant routes of delivery is of high importance.
Materials and Methods: The biodistribution of SPIONs (of two different sizes – 130 nm and 60 nm) radiolabeled with zirconium-89 or technetium-99m following intratumoral or intravenous injection was investigated in C57/Bl6 mice bearing subcutaneous GL261 glioblastomas. Based on PET/CT biodistribution data, a novel pharmacokinetic model was established for a better understanding of the pharmacokinetics of the SPIONs after both administration routes.
Results: The PET image analysis of the nanoparticles (confirmed by histology) demonstrated the presence of radiolabeled nanoparticles within the glioma site (with low amounts in the liver and spleen) at all investigated time points following intratumoral injection. The mathematical model confirmed the dynamic nanoparticle redistribution in the organism over a period of 72 h with an equilibrium reached after 100 h. Intravenous injection of nanoparticles demonstrated a different distribution pattern with a rapid particle retention in all organs (particularly in liver and spleen) and a subsequent slow release rate.
Conclusion: The mathematical model demonstrated good agreement with experimental data derived from tumor mouse models suggesting the value of this tool to predict the real-time pharmacokinetic features of SPIONs in vivo. In the future, it is planned to adapt our model to other nanoparticle formulations to more precisely describe their biodistribution in in vivo model systems.

Keywords: mathematical modeling, SPIONs, superparamagnetic iron oxide nanoparticles, pharmacokinetic model, glioblastoma, biodistribution

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]